0.77

1.85% 0.014

Novabay Pharmaceuticals Inc (NBY)

Overview News Price History Discussions Forecast Stock Split

Novabay Pharmaceuticals Inc stock is traded at $0.77, with a volume of 73,655. It is up +1.85% in the last 24 hours and up +8.45% over the past month. NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. NovaBay Pharmaceuticals, Inc. has collaboration and license agreement with Virbac to develop auriclosene, a proprietary compound for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.

Previous Close:

$0.756

Open:

$0.7625

24h Volume:

73,655

Relative Volume:

0.03

Market Cap:

$3.69M

Revenue:

$14.64M

Net Income/Loss:

$-13.74M

P/E Ratio:

-0.0735

EPS:

-10.47

Net Cash Flow:

$-5.04M

1W Performance:

+18.32%

1M Performance:

+8.45%

6M Performance:

-76.82%

1Y Performance:

-93.86%

1-Day Range:

$0.7373

$0.774

1-Week Range:

$0.606

$0.785

52-Week Range:

$0.3611

$12.78

Novabay Pharmaceuticals Inc Stock (NBY) Company Profile

Name

Novabay Pharmaceuticals Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

510-899-8800

Address

2000 Powell Street, Suite 1150, Emeryville, CA

Employee

Twitter

@NovaBayPharma

Next Earnings Date

2024-11-07

Latest SEC Filings

NBY's Discussions on Twitter

Novabay Pharmaceuticals Inc Stock (NBY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-18-19	Initiated	Ladenburg Thalmann	Buy
Jul-06-18	Reiterated	H.C. Wainwright	Buy
Nov-15-17	Reiterated	Laidlaw	Buy
Jun-05-17	Initiated	ROTH Capital	Buy
Mar-27-17	Initiated	Laidlaw	Buy
Feb-06-17	Initiated	Rodman & Renshaw	Buy
Mar-07-16	Downgrade	Maxim Group	Buy → Hold
Dec-14-15	Reiterated	Maxim Group	Buy
Apr-30-15	Resumed	Maxim Group	Buy
Mar-06-13	Initiated	Ascendiant Capital Markets	Strong Buy
Jan-03-08	Initiated	Dawson James	Speculative Buy

View All

Novabay Pharmaceuticals Inc Stock (NBY) Latest News

Nov 01, 2024

NovaBay Pharmaceuticals : Signs Distribution Agreement With the Biopharm Group - Marketscreener.com

Nov 01, 2024

Oct 31, 2024

# NovaBay Pharmaceuticals Considers Acquisition Offer in Recent SEC Filing - Defense World

Oct 31, 2024

Oct 29, 2024

NovaBay Pharmaceuticals receives unsolicited offer from Refresh Acquisitions - MSN

Oct 29, 2024

NovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLC - StockTitan

Oct 29, 2024

Sep 26, 2024

NovaBay Pharmaceuticals Signs Definitive Agreement to Sell Its Avenova Assets - Vision Monday

Sep 26, 2024

Sep 25, 2024